Table 1.
Demographic and clinical characteristics of the patients at baseline, n (%)
| Characteristic | AG | GEM | P value |
| Age in yr | 57 (40-72) | 59 (31-67) | |
| Sex | 0.787 | ||
| Male | 19 (63) | 20 (67) | |
| Female | 11 (37) | 10 (33) | |
| Performance status | 0.791 | ||
| 0 | 19 (63.3) | 18 (60) | |
| 1 | 11 (36.7) | 12 (40) | |
| Diabetes | 0.559 | ||
| No | 23 (77) | 21 (70) | |
| Yes | 7 (23) | 9 (30) | |
| Operative procedure | 0.605 | ||
| Pancreatoduodenectomy | 15 (50) | 17 (57) | |
| Distal pancreatectomy | 15 (50) | 13 (43) | |
| Residual tumor status | 0.687 | ||
| R0 | 27 (90) | 26 (87) | |
| R1 | 3 (10) | 4 (13) | |
| Primary tumor status | 0.638 | ||
| T1 | 6 (20.0) | 3 (10.0) | |
| T2 | 17 (56.7) | 20 (66.7) | |
| T3 | 5 (16.6) | 6 (20.0) | |
| T4 | 2 (6.7) | 1 (3.3) | |
| Regional lymph node status | 0.273 | ||
| N0 | 22 (73) | 18 (60) | |
| N1 | 8 (27) | 12 (40) | |
| Pathological stage | 0.405 | ||
| I (IA/IB) | 17 (5/12, 56.7) | 13 (1/12, 43.4) | |
| II (IIA/IIB) | 11 (4/7, 36.6) | 16 (5/11, 53.3) | |
| III | 2 (6.7) | 1 (3.3) | |
| Tumor grade | 0.105 | ||
| Well differentiated | 3 (10) | 2 (6.7) | |
| Moderately differentiated | 23 (76.7) | 17 (56.7) | |
| Poorly differentiated | 4 (13.3) | 11 (36.6) | |
| Pre-adjuvant CA19-9, median | 48.2 | 24.6 | 0.795 |
| ≤ 37 U/mL | 13 (43.4) | 14 (46.7) | |
| > 37 U/mL | 17 (56.6) | 16 (53.3) |
AG: Nab-paclitaxel plus gemcitabine; GEM: Gemcitabine.